Revolution Medicines is trading at $185.65, up 4.25% on November 6, 2026, after its November 4 earnings report showed RASONQUE generated $197.6 million in net product revenue in about five weeks.
- Nasdaq’s news feed characterized the quarter as beating estimates.
- Shares fell 11.04% on November 5 as broad markets rebounded November 6. The move may reflect reassessment of launch results; a news report also described shares trading higher following earnings.